Diagnostic Hybrids is now a wholly owned subsidiary of Quidel.

 


Diagnostic HYBRIDS Releases D3 Ultra(TM) DFA Respiratory Virus Screening & ID Kit

January 15, 2007

Athens, OH – Diagnostic HYBRIDS announces the release of the D3 UltraTM DFA Respiratory Virus Screening & Identification Kit. This second generation kit contains an increased number and better quality of antibodies for the detection of Influenza A, Influenza B, Parainfluenza 1, 2 and 3, Respiratory Syncytial Virus and Adenovirus.

The new Ultra kit offers a significant improvement in detection of Influenza B, Parainfluenza 3 and Adenovirus with no increase in background effects or non-specific results because of the improved antibodies. The one-step direct detection kit allows users to identify and differentiate seven major respiratory viruses in a 15-minute direct stain process, and it can be used for direct specimen testing as well as culture confirmation. 

According to Steven Geimer, Vice President of Sales, Marketing & Service at Diagnostic HYBRIDS, “5% to 20% of the U.S. population gets the flu each year, with Influenza A and B being the two main types of influenza virus associated with the flu illness. RSV is the most common cause of pneumonia and other respiratory diseases in children under 1 year of age. The D3 UltraTM DFA kit makes it easy and cost-effective to identify those patients with severe respiratory illness regardless of the infecting virus (Influenza A or B, RSV, Adenovirus, Parainfluenza 1, 2 or 3).”

About Diagnostic HYBRIDS
Diagnostic HYBRIDS develops and commercializes innovative and genetically engineered cell-based detection products for virus and autoimmune human diagnostic applications and for the pharmaceutical and biotechnology industry with an initial focus on pharmacology assays and products that measure drug clearance and anti-viral interventions with drugs and vaccines. The company is certified to ISO 13485 standards and manufactures live continuous and primary cell cultures for clinical diagnostics and pharmacology assays from its headquarters in Athens, OH. Diagnostic HYBRIDS was named one of the 500 Fastest Growing Companies in America in 2004 and 2005 by Inc. Magazine. The company is a pillar member of Omeris, a statewide organization of bioscience companies accelerating the bioscience and healthcare economy in Ohio. For more information, please visit www.dhiusa.com.

Contact:
Christina Dierkes
Coordinator, Marketing Communications & Public Relations
christina_dierkes@dhiusa.com
p: 740-597-2928